Mitochondria in Alzheimer's Disease Pathogenesis
- PMID: 38398707
- PMCID: PMC10890468
- DOI: 10.3390/life14020196
Mitochondria in Alzheimer's Disease Pathogenesis
Abstract
Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder that primarily affects persons aged 65 years and above. It causes dementia with memory loss and deterioration in thinking and language skills. AD is characterized by specific pathology resulting from the accumulation in the brain of extracellular plaques of amyloid-β and intracellular tangles of phosphorylated tau. The importance of mitochondrial dysfunction in AD pathogenesis, while previously underrecognized, is now more and more appreciated. Mitochondria are an essential organelle involved in cellular bioenergetics and signaling pathways. Mitochondrial processes crucial for synaptic activity such as mitophagy, mitochondrial trafficking, mitochondrial fission, and mitochondrial fusion are dysregulated in the AD brain. Excess fission and fragmentation yield mitochondria with low energy production. Reduced glucose metabolism is also observed in the AD brain with a hypometabolic state, particularly in the temporo-parietal brain regions. This review addresses the multiple ways in which abnormal mitochondrial structure and function contribute to AD. Disruption of the electron transport chain and ATP production are particularly neurotoxic because brain cells have disproportionately high energy demands. In addition, oxidative stress, which is extremely damaging to nerve cells, rises dramatically with mitochondrial dyshomeostasis. Restoring mitochondrial health may be a viable approach to AD treatment.
Keywords: Alzheimer’s disease; electron transport chain; inflammation; mitochondria.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Birnbaum J.H., Wanner D., Gietl A.F., Saake A., Kündig T.M., Hock C., Nitsch R.M., Tackenberg C. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients. Stem Cell. Res. 2018;27:121–130. doi: 10.1016/j.scr.2018.01.019. - DOI - PubMed
-
- Tapias V., González-Andrés P., Peña L.F., Barbero A., Núñez L., Villalobos C. Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease. Antioxidants. 2023;12:1282. doi: 10.3390/antiox12061282. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
